1. Home
  2. TNXP vs OPRT Comparison

TNXP vs OPRT Comparison

Compare TNXP & OPRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNXP
  • OPRT
  • Stock Information
  • Founded
  • TNXP 2007
  • OPRT 2005
  • Country
  • TNXP United States
  • OPRT United States
  • Employees
  • TNXP N/A
  • OPRT N/A
  • Industry
  • TNXP Biotechnology: Pharmaceutical Preparations
  • OPRT Finance: Consumer Services
  • Sector
  • TNXP Health Care
  • OPRT Finance
  • Exchange
  • TNXP Nasdaq
  • OPRT Nasdaq
  • Market Cap
  • TNXP 173.9M
  • OPRT 312.5M
  • IPO Year
  • TNXP N/A
  • OPRT 2019
  • Fundamental
  • Price
  • TNXP $19.47
  • OPRT $5.72
  • Analyst Decision
  • TNXP Buy
  • OPRT Sell
  • Analyst Count
  • TNXP 1
  • OPRT 2
  • Target Price
  • TNXP $70.00
  • OPRT $6.00
  • AVG Volume (30 Days)
  • TNXP 858.1K
  • OPRT 597.0K
  • Earning Date
  • TNXP 11-11-2025
  • OPRT 11-04-2025
  • Dividend Yield
  • TNXP N/A
  • OPRT N/A
  • EPS Growth
  • TNXP N/A
  • OPRT N/A
  • EPS
  • TNXP N/A
  • OPRT N/A
  • Revenue
  • TNXP $9,831,000.00
  • OPRT $724,757,000.00
  • Revenue This Year
  • TNXP $14.79
  • OPRT $26.95
  • Revenue Next Year
  • TNXP $933.49
  • OPRT $5.74
  • P/E Ratio
  • TNXP N/A
  • OPRT N/A
  • Revenue Growth
  • TNXP N/A
  • OPRT N/A
  • 52 Week Low
  • TNXP $6.76
  • OPRT $2.51
  • 52 Week High
  • TNXP $130.00
  • OPRT $9.25
  • Technical
  • Relative Strength Index (RSI)
  • TNXP 33.39
  • OPRT 49.21
  • Support Level
  • TNXP $18.53
  • OPRT $5.30
  • Resistance Level
  • TNXP $20.55
  • OPRT $5.63
  • Average True Range (ATR)
  • TNXP 1.23
  • OPRT 0.24
  • MACD
  • TNXP 0.39
  • OPRT 0.05
  • Stochastic Oscillator
  • TNXP 22.96
  • OPRT 85.44

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

About OPRT Oportun Financial Corporation

Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.

Share on Social Networks: